US OptionsDetailed Quotes

AUPH240816C6000

Watchlist

0.20
-0.13-39.39%

15min DelayClose Jul 22 15:59 ET

0.35High0.15Low

Aurinia Pharmaceuticals Stock Discussion

frogoracletrading

Jun 3 21:51

$AUPH Support / Resistance Levels

Basing around 5.35 if that holds look for a retest of the 5.80 area.
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US)$

Jaguar8

May 14 05:02

$Aurinia Pharmaceuticals(AUPH.US)$
NEWS
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS ...

frogoracletrading

May 2 07:41

$AUPH Support / Resistance Levels

AUPH been getting some pops last couple days. Here are the levels to watch.
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US)$

Jaguar8

Apr 30 05:41

$Aurinia Pharmaceuticals(AUPH.US)$
NEWS
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required af...

Moomoo AI

Feb 15 06:17

The company's missed forecasts and lack of positive strategic review results may dampen investor sentiment. However, cost savings from discontinuing early-stage drugs and reducing staff, along with share buybacks, could offset some negativity.

Aurinia Drops After Q4 Miss; Strategic Review Fails

Moomoo AI

Feb 5 04:47

Recent insider selling activity and lack of trades in the last quarter at Aurinia Pharmaceuticals may concern investors. However, modest insider ownership could suggest alignment between management and smaller shareholders.

Aurinia Pharmaceuticals Insiders Sell US$1.8m Of Stock, Possibly Signalling Caution

Moomoo AI

Jan 5 07:07

Shareholders may not be comfortable amid potentially dimmer future expectations for the company, possibly causing the lower P/S ratio. A shift in the company's fortunes would be required to justify an increase in the P/S.

The Market Doesn't Like What It Sees From Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Revenues Yet

Moomoo AI

Dec 18, 2023 05:28

High confidence in Aurinia Pharmaceuticals with anticipated average yearly growth rate of 71%. A slower rate will delay profitability. Company's debt-free status lowers investment risk.

When Can We Expect A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?

Moomoo AI

Nov 30, 2023 05:42

If the company can sustain its revenue growth, the share price may further increase. The company's performance appears to have improved recently, as the one-year total shareholder return is better than the five-year total shareholder return.

Even Though Aurinia Pharmaceuticals (NASDAQ:AUPH) Has Lost US$63m Market Cap in Last 7 Days, Shareholders Are Still up 68% Over 1 Year

ricko

Nov 19, 2023 19:36

$Aurinia Pharmaceuticals(AUPH.US)$ I'm watching this one

No comment yet